台股 » 個股 » 生華科 » 籌碼相關 » 券商分點績效

生華科

(6492)
可現股當沖
  • 股價
    41.70
  • 漲跌
    --
  • 漲幅
    0.00%
  • 成交量
    246
  • 產業
    上櫃 生技醫療類股
  • 147人加入追蹤

    立即追蹤

  • 本地時間:14:30

     
生華科 (6492)籌碼相關-券商分點績效/獲利分析
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

«前一日     2024/04/16 ~ 2024/04/30     後一日»

券商獲利排行 - 2024/04/16 ~ 2024/04/30

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  2.39%44.7044.74646040.740.7041.7
  1.11%34.46.527.946752941.241.141.341.7
  2.54%330333232040.740.741.441.7
  2.21%22.6022.62425140.840.840.841.7
  1.79%17.73.813.92024441.1414241.7
  1.82%15.87.48.411211041.240.941.741.7
  0.62%13.8-1.715.54554941.341.441.241.7
  1.44%11.9011.92020041.141.1041.7
  1.30%10.7010.72020041.241.241.441.7
  2.14%10.50.110.41012240.740.740.741.7
  0.47%9.1-5.114.331471641.241.240.941.7
  1.10%9091820241.241.241.241.7
  2.43%8.908.999040.740.7041.7
  2.74%8.908.988040.640.6041.7
  1.75%8.61.27.41112141.14142.341.7
  2.45%80.97.178140.840.741.641.7
  2.38%7.707.778040.740.740.941.7
  1.09%7.73.24.51017741.441.341.741.7
  1.77%7.334.3610441.24141.741.7
  1.96%7.207.289140.840.840.841.7
  2.42%6.906.977040.740.7041.7
  2.38%6.80.8667140.840.741.541.7
  1.06%6.5-0.77.21215341.141.140.941.7
  0.95%606-1501542.1042.141.7
  2.25%5.505.566040.840.8041.7
  0.82%5.105.11515041.441.4041.7
  2.48%50555040.740.7041.7
  2.96%4.804.844040.540.5041.7
  2.30%4.704.755040.840.8041.7
  1.25%4.604.699041.241.240.741.7
  1.87%4.604.666040.940.94141.7
  1.53%4.404.477041.141.1041.7
  0.16%4.31.82.64666241.141.141.141.7
  2.58%4.204.244040.740.7041.7
  1.00%4.21.52.7-911041.940.54241.7
  2.01%4.104.155040.940.9041.7
  1.65%4.13.50.616541.441.141.841.7
  2.46%40444040.740.7041.7
  2.46%40444040.740.741.441.7
  2.42%41.32.634141.140.842.241.7
  1.60%3.9-0.24.156140.940.940.741.7
  1.90%3.903.955040.940.941.441.7
  1.82%3.70.43.345140.940.941.341.7
  1.81%3.703.75504141041.7
  2.96%3.603.633040.540.5041.7
  0.65%3.503.51313041.441.4041.7
  1.42%3.503.566041.141.1041.7
  0.60%3.45.4-1.9-581441.140.741.441.7
  0.34%3.412.4-2212441.840.841.841.7
  1.66%3.403.45504141041.7

券商虧損排行 - 2024/04/16 ~ 2024/04/30

券商分點績效總損益(仟)己實現(仟)未實現(仟)買賣超買張賣張均價均買均賣現價
  -2.40%-81.2-1.3-79.9-8218340.74240.741.7
  -2.15%-54.4-1.2-53.2-5936240.841.240.841.7
  -1.79%-36.80-36.8-500504104141.7
  -2.12%-32.90-32.9-3803840.8040.841.7
  -2.35%-30.1-23.5-6.6-8233141.341.940.941.7
  -2.57%-18.80-18.8-1801840.7040.741.7
  -0.45%-13.61.8-15.4-61117241.441.341.441.7
  -2.96%-120-12-1001040.5040.541.7
  -0.43%-10.3-132.87585141.241.34141.7
  -0.43%-9.1-5.3-3.8-7445141.241.341.241.7
  -1.22%-7.6-1-6.6-1041541.241.441.141.7
  -2.46%-70-7-60740.742.540.741.7
  -0.44%-6.80.4-7.2-3423741.541.341.541.7
  -2.39%-6.8-1.3-5.5-42740.741.340.641.7
  -2.31%-6.60-6.6-60740.842.540.841.7
  -3.22%-6.50-6.5-50540.4040.441.7
  -1.58%-6.5-2.4-4.1-461040.841.140.741.7
  -1.41%-6.40-6.4-1101141.1041.141.7
  -1.55%-6.3-0.3-6.1-82104141.140.941.7
  -2.17%-6.2-0.5-5.7-51740.841.240.741.7
  -2.96%-60-6-50540.5040.541.7
  -2.91%-5.90-5.9-40540.541.140.541.7
  -2.35%-5.8-2.2-3.6-32641.141.940.841.7
  -2.86%-5.80-5.8-40540.542.540.541.7
  -0.77%-5.70.1-5.8-8918414141.141.7
  -0.81%-5.70.3-6-1251741.241.141.241.7
  -1.12%-5.6-0.1-5.5-1111241.241.341.241.7
  -0.63%-5.5-1.3-4.2-4162140.940.940.941.7
  -1.45%-5.40.2-5.6-7194140.84141.7
  -1.55%-5.10-5.1-80841.1041.141.7
  -1.21%-50-5-1001041.242.241.241.7
  -2.44%-50-5-40540.740.640.741.7
  -1.52%-4.4-0.9-3.5-61741.242.141.141.7
  -1.41%-4.1-1.8-2.35724242.241.341.7
  -1.23%-4.1-0.2-3.8-71841.241.441.241.7
  -2.46%-40-4-40440.7040.741.7
  -2.46%-40-4-40440.7040.741.7
  -1.21%-4-2.9-107840.941.140.741.7
  -2.39%-3.90-3.9-30440.742.240.741.7
  -2.36%-3.90-3.9-40440.7040.741.7
  -1.87%-3.80-3.8-50540.94240.941.7
  -0.54%-3.80-3.8-1601741.541.941.541.7
  -0.36%-3.8-1-2.8-5212641.241.241.141.7
  -2.92%-3.60-3.6-30340.5040.541.7
  -1.21%-3.50-3.5-60741.241.341.241.7
  -1.71%-3.50-3.5-4054142.34141.7
  -1.38%-3.40-3.4-60641.1041.141.7
  -1.32%-3.30-3.3-60641.2041.241.7
  -1.32%-3.30-3.3-60641.2041.241.7
  -1.96%-3.20-3.2-40440.9040.941.7
上櫃「肥貓」董監現形 台嘉碩、大宇資、穩懋、生華科為前四肥Anue鉅亨-2024/04/15
生華科治療新冠、流感等泛病毒感染新藥 將啟動二期臨床Anue鉅亨-2023/11/21
生華科泛病毒感染肺炎新藥 向美申請二期臨床Anue鉅亨-2023/10/19
生華科 相關文章
生華科 相關影音